focus -WSS

focus

author：explore 2025-10-02 01:04:42 - browse：39878

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： FDA approves first new drug developed for postpartum depression

focus

WSS

Resistance to opioid

ACIP vaccine advisory panel sees its vacancies filled

Bernie Sanders gets little from pharma CEOs on drug prices

ACIP vaccine advisory panel sees its vacancies filled

Congress must protect the remaining independent doctors

Report cites 'urgent' need to recruit more diverse clinical trial participants

explore

focus

hotspot

In age of alternative facts, a scholarly course on calling out crap

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Congress must protect the remaining independent doctors

Heart attack and stroke risk calculators need revising

Can medical device makers keep up in the race to treat obesity?

Continuity nursing helped my family in our darkest PICU moments

Senate panel passes drug pricing bills, but drops one PBM reform

Drug repurposing or repositioning? The language matters

Latigo launches with $135 million for Vertex

hotspot

Timeline: Key moments in fight for gay rights

Ebola vaccine can save some who are already sick, per new study

Why don't Americans have at

Senate panel passes drug pricing bills, but drops one PBM reform

Timeline: Key moments in fight for gay rights

Tome Biosciences co

knowledge

hotspot

focus

Wikipedia